Protagonist Therapeutics (PTGX) Competitors $51.20 +0.51 (+1.01%) Closing price 07/3/2025 02:41 PM EasternExtended Trading$51.18 -0.03 (-0.05%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTGX vs. RDY, ASND, VTRS, QGEN, MRNA, BPMC, VRNA, BBIO, ROIV, and RVMDShould you be buying Protagonist Therapeutics stock or one of its competitors? The main competitors of Protagonist Therapeutics include Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Protagonist Therapeutics vs. Its Competitors Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Qiagen Moderna Blueprint Medicines Verona Pharma PLC American Depositary Share BridgeBio Pharma Roivant Sciences Revolution Medicines Protagonist Therapeutics (NASDAQ:PTGX) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk. Which has higher valuation & earnings, PTGX or RDY? Dr. Reddy's Laboratories has higher revenue and earnings than Protagonist Therapeutics. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtagonist Therapeutics$434.43M7.30$275.19M$0.7568.27Dr. Reddy's Laboratories$3.81B3.30$663M$0.6622.85 Do insiders and institutionals have more ownership in PTGX or RDY? 98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 4.9% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk and volatility, PTGX or RDY? Protagonist Therapeutics has a beta of 2.26, suggesting that its share price is 126% more volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Is PTGX or RDY more profitable? Protagonist Therapeutics has a net margin of 27.04% compared to Dr. Reddy's Laboratories' net margin of 17.38%. Dr. Reddy's Laboratories' return on equity of 17.98% beat Protagonist Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protagonist Therapeutics27.04% 9.22% 8.31% Dr. Reddy's Laboratories 17.38%17.98%12.24% Does the media favor PTGX or RDY? In the previous week, Protagonist Therapeutics had 3 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 5 mentions for Protagonist Therapeutics and 2 mentions for Dr. Reddy's Laboratories. Protagonist Therapeutics' average media sentiment score of 0.54 beat Dr. Reddy's Laboratories' score of 0.36 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate PTGX or RDY? Protagonist Therapeutics currently has a consensus target price of $66.10, indicating a potential upside of 29.10%. Dr. Reddy's Laboratories has a consensus target price of $16.95, indicating a potential upside of 12.40%. Given Protagonist Therapeutics' higher probable upside, research analysts plainly believe Protagonist Therapeutics is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00Dr. Reddy's Laboratories 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryProtagonist Therapeutics beats Dr. Reddy's Laboratories on 11 of the 15 factors compared between the two stocks. Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTGX vs. The Competition Export to ExcelMetricProtagonist TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.16B$2.91B$5.54B$9.05BDividend YieldN/A2.44%5.24%4.02%P/E Ratio68.2721.5627.4320.22Price / Sales7.30281.76416.87118.64Price / Cash11.3042.7336.8958.07Price / Book4.527.518.035.67Net Income$275.19M-$55.05M$3.18B$249.13M7 Day Performance-8.06%4.61%2.88%3.28%1 Month Performance-4.87%4.72%3.69%5.56%1 Year Performance51.84%5.92%36.02%21.12% Protagonist Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTGXProtagonist Therapeutics2.1369 of 5 stars$51.20+1.0%$66.10+29.1%+48.4%$3.16B$434.43M68.27120RDYDr. Reddy's Laboratories2.8048 of 5 stars$15.31+0.5%$16.95+10.7%-0.9%$12.71B$3.81B23.2027,811ASNDAscendis Pharma A/S3.6652 of 5 stars$175.78-0.6%$220.67+25.5%+29.7%$10.81B$393.54M-27.991,017News CoverageAnalyst ForecastVTRSViatris3.306 of 5 stars$8.85-0.2%$10.40+17.5%-10.9%$10.41B$14.74B-2.7932,000QGENQiagen4.0454 of 5 stars$46.72-0.1%$47.74+2.2%+22.5%$10.39B$1.98B117.145,765Dividend AnnouncementMRNAModerna4.3808 of 5 stars$25.67-0.9%$46.61+81.6%-73.7%$10.02B$3.24B-2.945,800Options VolumeBPMCBlueprint Medicines1.5724 of 5 stars$128.40+0.2%$128.06-0.3%+17.6%$8.28B$508.82M-51.98640High Trading VolumeVRNAVerona Pharma PLC American Depositary Share2.6171 of 5 stars$97.05+2.9%$101.10+4.2%+480.4%$8.03B$42.28M-48.5330Analyst ForecastBBIOBridgeBio Pharma4.7073 of 5 stars$42.17+1.1%$56.67+34.4%+74.8%$7.92B$221.90M-11.95400News CoverageInsider TradeAnalyst RevisionROIVRoivant Sciences1.5558 of 5 stars$11.50+0.4%$17.50+52.2%+3.5%$7.78B$29.05M-46.00860RVMDRevolution Medicines4.5904 of 5 stars$40.04+1.0%$67.08+67.5%+0.2%$7.39B$11.58M-10.01250Analyst Revision Related Companies and Tools Related Companies Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives Qiagen Alternatives Moderna Alternatives Blueprint Medicines Alternatives Verona Pharma PLC American Depositary Share Alternatives BridgeBio Pharma Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTGX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
